Reliability Of 124I-evuzamitide Imaging and Quantitative Agreement in Patients with AL and ATTR Systemic Amyloidosis

Mar 31, 2025 Posters & Publications

Click Here to View...

Automated Quantification of AL and ATTR Systemic Amyloid Burden Using 124I-evuzamitide, a Novel Pan-Amyloid Radiotracer

Mar 31, 2025 Posters & Publications

Click Here to View...

Diagnostic Performance of Cardiac and Whole-Body 124I-Evuzamitide (AT-01) PET/MRI in Systemic Amyloidosis

Mar 29, 2025 Posters & Publications

Click Here to View...

Attralus Announces Enrollment of First Patient in Phase 3 Trial for the Pan-Amyloid Diagnostic 124I-evuzamitide (AT-01) for Cardiac Amyloidosis

Jan 15, 2025 Press Releases

PDF Version Phase 3 – REVEAL study for iodine 124I-evuzamitide (AT-01) in patients with suspected cardiac amyloidosis has begun enrollment by Brigham and Women’s Hospital, Boston MA, in conjunction with Attralus. Attralus is developing 124I-evuzamitide as the first...

Attralus Receives Breakthrough Therapy Designation for its Pan-Amyloid Diagnostic PET Imaging Candidate 124I-evuzamitide (AT-01) for Cardiac Amyloidosis

Aug 5, 2024 Press Releases

PDF Version 124I-evuzamitide (AT-01) is one of the first investigational diagnostic imaging agents to receive Breakthrough Therapy Designation (BTD) from the US Food and Drug Administration (FDA), and the only diagnostic imaging agent that has received BTD for cardiac...